China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
3.560
-0.240 (-6.32%)
Aug 25, 2026, 12:08 PM EDT - Market open
China SXT Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 28.18 | 18.1 | 12.07 | 17.37 | 15.52 |
Short-Term Investments | 0.14 | 0.14 | - | - | - |
Cash & Short-Term Investments | 28.32 | 18.24 | 12.07 | 17.37 | 15.52 |
Cash Growth | 55.30% | 51.09% | -30.50% | 11.88% | 16.43% |
Accounts Receivable | 0.93 | 1.3 | 1.31 | 1.34 | 3.37 |
Other Receivables | 2.2 | 0.47 | 0.03 | 0.23 | 0.66 |
Receivables | 3.23 | 1.9 | 1.35 | 1.58 | 5.53 |
Inventory | 2.96 | 1.13 | 0.81 | 0.58 | 1.07 |
Restricted Cash | 0 | 0.03 | 0.01 | - | 0.05 |
Other Current Assets | - | - | - | - | 0.29 |
Total Current Assets | 34.51 | 21.3 | 14.23 | 19.52 | 22.45 |
Property, Plant & Equipment | 0.24 | 0.36 | 0.56 | 1.27 | 1.59 |
Other Intangible Assets | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 |
Other Long-Term Assets | - | - | 8.31 | 8.74 | 9.46 |
Total Assets | 34.75 | 21.66 | 23.13 | 29.55 | 33.55 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 0.5 | 1.16 | 1.28 | 1.38 | 1.48 |
Accrued Expenses | 1.93 | 1.78 | 1.59 | 1.74 | 2.01 |
Short-Term Debt | 0.36 | 0.7 | 3.32 | 8.53 | 10.73 |
Current Portion of Long-Term Debt | - | 0.01 | 0.02 | 0.01 | 0.01 |
Current Portion of Leases | 0.07 | 0.06 | 0.06 | 0.06 | - |
Current Income Taxes Payable | 0 | 1.03 | 1.05 | 1.1 | 1.17 |
Current Unearned Revenue | 0.1 | 0.06 | 0.19 | 0.17 | - |
Other Current Liabilities | 1.39 | 1.21 | 1.39 | 1.52 | 1.72 |
Total Current Liabilities | 4.35 | 6.01 | 8.9 | 14.5 | 17.12 |
Long-Term Debt | 0.64 | 0.1 | 0.12 | 0.12 | - |
Long-Term Leases | 0.05 | 0.12 | 0.18 | 0.25 | - |
Total Liabilities | 5.05 | 6.22 | 9.2 | 14.86 | 17.12 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 64.13 | 44.53 | 39.67 | 0.91 | 0.16 |
Additional Paid-In Capital | - | - | - | 35.59 | 30.99 |
Retained Earnings | -34.22 | -28.02 | -24.71 | -21.61 | -15.69 |
Comprehensive Income & Other | -0.2 | -1.08 | -1.03 | -0.2 | 0.96 |
Shareholders' Equity | 29.71 | 15.44 | 13.93 | 14.69 | 16.42 |
Total Liabilities & Equity | 34.75 | 21.66 | 23.13 | 29.55 | 33.55 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 1.12 | 0.98 | 3.7 | 8.96 | 10.74 |
Net Cash (Debt) | 27.2 | 17.25 | 8.38 | 8.41 | 4.78 |
Net Cash Growth | 57.65% | 106.00% | -0.39% | 75.82% | 319.07% |
Net Cash Per Share | - | - | - | - | 2.35 |
Filing Date Shares Outstanding | 0.4 | 0.01 | 0 | 0 | 0 |
Total Common Shares Outstanding | 0.01 | 0 | 0 | 0 | 0 |
Working Capital | 30.16 | 15.28 | 5.33 | 5.02 | 5.33 |
Book Value Per Share | 2480.58 | 13461.00 | 605671.57 | 2938259.00 | 16424708.00 |
Tangible Book Value | 29.7 | 15.43 | 13.91 | 14.66 | 16.39 |
Tangible Book Value Per Share | 2480.05 | 13450.70 | 604841.09 | 2932685.40 | 16385946.00 |
Machinery | 1.1 | 1.04 | 1.19 | 1.24 | 1.27 |
Construction In Progress | - | - | - | - | 0.36 |
Leasehold Improvements | 1.64 | 1.56 | 1.56 | 1.64 | 1.78 |